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Abstract
IGF signaling is involved in cell proliferation, differentiation and apoptosis in a wide range of tissues, both normal and
diseased, and so IGF-IR has been the focus of intense interest as a promising drug target. In this computational study on
cartilage, we focus on two questions: (i) what are the key factors influencing IGF-IR complex formation, and (ii) how might
cells regulate IGF-IR complex formation? We develop a reaction-diffusion computational model of the IGF system involving
twenty three parameters. A series of parametric and sensitivity studies are used to identify the key factors influencing IGF
signaling. From the model we predict the free IGF and IGF-IR complex concentrations throughout the tissue. We estimate
the degradation half-lives of free IGF-I and IGFBPs in normal cartilage to be 20 and 100 mins respectively, and conclude that
regulation of the IGF half-life, either directly or indirectly via extracellular matrix IGF-BP protease concentrations, are two
critical factors governing the IGF-IR complex formation in the cartilage. Further we find that cellular regulation of IGF-II
production, the IGF-IIR concentration and its clearance rate, all significantly influence IGF signaling. It is likely that negative
feedback processes via regulation of these factors tune IGF signaling within a tissue, which may help explain the recent
failures of single target drug therapies aimed at modifying IGF signaling.
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Introduction
The insulin-like growth factor system is comprised of two
insulin-like growth factors (i.e. IGF-I and –II), type I and II IGF
receptors (i.e. IGF-IR and IGF-IIR), insulin receptor (IR), a family
of IGF binding proteins (here we focus on IGFBP1 through to
IGFBP6) and IGFBP-degrading proteases [1] (see Figure 1 for
schematic). Growth hormone regulates the IGF-I production by
the liver, which is the source of the majority of IGF-I found in
plasma [2]. On the other hand, IGF-II and IGFBPs found in the
serum are most likely sourced from a variety of tissues (e.g. liver,
muscle, brain, kidney being the principal sources) [3,4].
IGF signalling through the type I IGF receptor (IGF-IR) is
involved in cell proliferation, differentiation, apoptosis and general
anabolic cell processes (including the production of extra cellular
matrix) [5]. An absence of IGF leads to growth hormone resistant
growth failure, which may be treated using the synthetic IGF
mecasermin [6]. A low level of IGF-I has also been shown to be
associated with insulin-dependent diabetes in children and
cardiovascular disease in adults [7].
Excessive levels of IGFs in the circulation are linked with an
increased risk of cancer [1,8,9,10], and there is some compelling
evidence that the IGF/IGF-IR system plays a major role in some
types of human neoplasm [11,12]. Intervening in the IGF
signaling system has been identified as an attractive strategy for
the treatment of certain human cancers [13]. For example, the
reduction in IGF-IR activation by the binding of specific
antibodies leads to apoptosis of cancer cells [14,15]. A recent
study using the monoclonal antibody ‘Figitumumab’, supported
the potential therapeutic efficacy of anti-IGF-IR strategies for the
treatment of patients with Ewing’s sarcoma [16]. However several
drug companies have recently stopped development of drugs
designed to block IGF-R signaling, expressing frustration over the
ineffectiveness of drugs that have been developed, blaming the
biological complexity of the IGF system [17]. Based on the hard
won (negative) findings, it is now clearly apparent that a ‘systems
approach’ is needed to understand why a single drug target may
be ineffective for managing IGF-IR signaling. Indeed, it points to
the fact that several drugs acting together may be required to
effectively block a signaling pathway. From a sensitivity analysis
for our model, we find that it is likely that negative feedback
processes act to neutralize the effect of attempting to block a single
target.
It is expected that treatment of patients with a variety of disease
processes in all tissues of the body may be enhanced when there is
an improved understanding of the processes that regulate the cell’s
exposure to IGF within a tissue from a circulating source of IGF.
To contribute towards this goal, this paper is focused developing a
systems model to estimate the free and total IGF concentrations
within a single tissue – articular cartilage. Cartilage was chosen
primarily because we are aware of appropriate data to enable
calibration of the model.
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IGF-I and IGF-II (and insulin in high concentrations) bind to
the IGF-IR receptor, leading to activation of a receptor tyrosine
kinase and subsequent downstream signaling via the AKT
pathway. The strength of activation of the signaling (for a fixed
receptor concentration) depends on the fraction of overall
receptors that have formed a complex with their ligands. However
the downstream pathway activation need not be proportional to
the receptor occupancy. For example, previous studies on cartilage
have shown there is a certain threshold of IGF-I/ IGF-IR
concentration that needs to be exceeded before protein synthesis is
activated [18,19]. In this paper IGF-IR complex formation is
included, but no downstream signaling processes are modeled, so
the IGF-IR complex concentration is adopted here as the primary
biological marker of functional activity due to IGFs in the tissue.
Although IGF-II is widely argued to play an important role in
embryonic and foetal life [1,20], recent studies indicate that IGF-II
is also important in adults for muscle, brain and other tissues by
signaling through the receptor IGF-IR [4,21]. While many tissues
produce IGF-II, most tissues produce little or no IGF-I, with the
majority of IGF-I in tissues originating from production by the
liver [22]. Only IGF-II binds to the IGF-IIR receptor [23].
Formation of IGF-IIR complexes usually has no known down-
stream signaling consequences, although it has been reported that
binding of IGF-II to IGF-IIR may provide a possible mechanism
for the regulation of cardiomyocyte apoptosis [24]. Instead it is
thought that the primary role of the IGF-II-IGF-IIR complex is
the regulation of the IGF-II concentration in the tissue, i.e via
sequestration and removal of the IGF-II-IGF-IIR complex
through lysosomal degradation [25]. In other words, IGF-IIR is
postulated to be a ‘clearance receptor’.
One conceivable mechanism for regulating the IGF-IR receptor
complex concentration in the tissue (and so the IGF signaling
pathway) is to regulate the ratio of IGF-I and –II in the tissue, as
IGF-I and –II ligands competitively bind to IGF-IR. Note the
IGF-II concentration in human plasma is typically three-fold
higher than that of IGF-I [26], and the ratio of IGF-II/IGF-I may
reach over 300 in a tumor [27]. The functional significance of
these observations of IGF-II/IGF-I is yet to be fully appreciated.
A second possible mechanism for regulating the bioavailability
of the two IGFs to IGF-IR is to adjust the type of IGFBPs within
the tissue, e.g. by regulating the production of IGFBPs or the
removal of IGFBPs. Among the ten current known IGFBPs, at
least six of them (i.e. IGFBPs 1–6) bind IGFs with high affinity
[28,29,30,31]. While the full range of functional roles of the
binding proteins remains to be clarified, some of their actions are
known. First, IGFBPs can function as IGF carriers, protecting the
IGFs from degradation while they are being transported through
tissues [3,32]. It is well known that binding proteins can also act as
stores of IGFs within the tissue, which helps to smooth any
fluctuations in IGF production or transport over time [3].
It has been demonstrated theoretically, using a reactive-
diffusion transport model, that reversible binding between IGFs
and diffusible IGFBPs can significantly increase the uptake rate of
free IGF into a tissue) [33]. Most importantly, targeted degrada-
tion of IGF binding proteins can lead to substantial increases in the
free IGF concentration in the tissue, compared to the concentra-
Figure 1. Schematic diagram of the IGF system.
doi:10.1371/journal.pone.0066870.g001
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tion in the plasma, with the rate of degradation of the binding
proteins controlling the free IGF concentration in the tissue [34].
That is, tissue can potentially tune their exposure to IGF by
modifying the rate of degradation of the IGF binding partner.
Different IGFBP proteases may selectively target IGFBPs for
degradation, potentially giving fine control over the total IGF
concentration in the tissue and the ratio of IGF-I/IGF-II. For
example, serine protease is reported to be mainly responsible for
cleavage of IGFBP5 [35], whilst metalloproteinase ADAM 12-S
primarily degrades IGFBP3 and IGFBP5 but not IGFBP1, 22,
24 and 26 [36]. In addition, matrix metalloproteinases (MMPs)
are capable of increasing bioavailability of IGF-I by degrading
IGFBP 1, 23, and 25 [37]. IGFBP6 is an O-linked glycoprotein.
It is known that O-glycosylation inhibits human IGFBP6
degradation by chymotryspin and tryspin [38]. In addition, O-
glycosylation also helps maintain IGFBP6 in soluble form by
inhibiting its binding to glycosaminoglycans and cell membranes
[38]. These targeted mechanisms provide tissue with the means to
adjust their free IGF concentration. That is, cells in tissues can
‘tune’ their IGF exposure, effectively independently to the plasma
concentration, to suit the tissue’s particular needs. It is expected
that these tuning processes would contribute to the maintenance of
tissue homeostasis.
IGFBPs are also capable of blocking IGFs access to IGF
receptors (e.g. IGF-IR) through sequestration. IGFs have a 2–50
fold greater affinity for IGFBPs than that of the IGF-IR receptor
itself [1,39]. It has been theoretically demonstrated that extracel-
lular matrix (ECM) fixed IGFBPs within the tissue have no
influence on the steady-state free IGF-I and –II concentrations in
the tissue if the half-lives of these ECM fixed IGFBPs are
prolonged by ECM proteins [33]. IGF-independent cellular
actions of the IGFBPs have also been reported [3,34].
Among six IGFBPs (i.e. IGFBP1-6), IGFBP1-5 have approxi-
mately similar affinities for IGF-I and –II, but IGFBP6 has a 20–
100 fold higher affinity for IGF-II than for IGF-I [40,41,42].
Because of the similar affinities, as a good approximation for many
purposes, one may simply sum the concentrations of IGFBP1–5,
and treat this as one functional group of BPs, and treat IGFBP6 as
a second functional group. In our previous study [43], we have
theoretically demonstrated that Bhakt et al’s experimental results
for equilibrium competitive binding [44] can be successfully
reproduced using a reversible Langmuir sorption isotherm
involving these two ‘functional groupings’ of IGFBPs. The effect
of this competitive binding on ligand and complex formation will
be included in this study.
A third possible mechanism to regulate the IGF-IR receptor
complex concentration in the tissue is to regulate the IGF-IR
receptor density at the cell surface. Given a constant IGF
concentration, as the receptor density increases, so the total
number of IGF-IR receptor complexes will clearly increase. There
is also the possibility that cells may spatially vary their expression
of cell surface receptors throughout the tissue, which adds another
layer of complexity. This is an important area and will later on be
investigated in a parametric study.
Receptor behavior is complex. IGF-IR has significantly higher
binding preference for IGF-I and –II compared to insulin, whereas
IGF-IIR only preferentially binds IGF-II [23]. In comparison to
IGFBPs 1–6, IGFBP-7 lacks the important ternary structure
Figure 2. Schematic diagram shows the scope of this study.
doi:10.1371/journal.pone.0066870.g002
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required for binding IGFs with high affinity, but has the capability
of binding to insulin and subsequently inhibit insulin binding to
the insulin receptor (IR) [45]. Although IGFBP-7 has been
identified in human biological fluid, its concentration is too small
to detect in human cartilage [46], and so is not explicitly
considered in our model. The insulin receptor primarily regulates
cell metabolic functions [47]. Both IGF-IR and insulin receptors
are usually tyrosine kinase homodimers, but IGF-IR-insulin
heterodimers may form [5]. Hybrid receptors (IGF-IR/IR) formed
by IGF-IR and IR bind to IGF-I with at least 50-folder higher
affinity than insulin irrespective of the splice variant [48]. Homo-
and hetero-dimerisation of receptors is not considered here.
While much is known about the individual components making
up the IGF system, it still remains unclear how these components
act together as an integrated system within a tissue. Indeed, it is
likely that a ‘systems approach’ is required for the development of
more efficacious drug therapies. Our previous studies of cartilage
have been particularly focussed on the IGF-I mediated cartilage
ECM biosynthesis via IGF-IR [18,19,33,43,49,50,51,52,53]. In
this study, to achieve a system level of understanding of how tissues
regulate their exposure to growth factors and so maintain normal
tissue homeostasis and biological functions, we have developed a
computational model of IGF system in cartilage involving IGF-I,
IGF-II, insulin, IGF-IR, IGF-IIR and IR. Our aim is to identify
the critical model variables for potentially controlling IGF
signaling homeostasis based on a sensitivity analysis for the system.
It is expected that the cartilage model developed here could be
generalized further and applied to a range of different tissues in
health and disease.
Methods
The general outline of the IGF system is illustrated in Figure 1,
while the specific IGF system model considered in this paper is
illustrated in Figure 2. As shown in Figure 2, IGF-I and –II exert
their biological actions via competitively binding to IGF-IR,
whereas IGF-IIR mainly functions as an IGF-II ‘decoy’ receptor,
which is cleared by lysosomal degradation. To help demonstrate
the fundamental behaviours exhibited by the IGF system within a
complex tissue like cartilage, a simplification of the real system is
necessary. Here it is assumed that
N The bioavailability of two IGFs is regulated by two functional
groups of IGFBPs [43], that is, one group of binding proteins
has similar binding affinity to both IGF-I and –II (i.e. IGFBP1-
5), whereas the second group has only binding preference for
IGF-II (i.e. IGFBP6).
N Zero initial conditions are assumed within the cartilage for all
components except cells (specifically chondrocytes) which are
assumed to be uniformly distributed throughout the tissue,
however, it is noted that the steady-state solutions reported
here are independent of the initial conditions.
N Given that ECM bound IGFBPs have little influence on
steady-state IGF concentration [33] and the quantities of
IGFBP produced by human cartilage are relatively small in
comparison to the amount supplied from the circulation [54],
ECM fixed IGFBPs and the local expression of IGFBPs are not
explicitly considered in this study.
Referring to Figure 2 and using the law of mass action
[55,56,57], we obtained the following system of partial differential
equations describing the co-diffusion of the two IGFs, insulin and
the IGFBPs from synovial fluid into the cartilage and interacting
with IGF-IR, IGF-IIR and IR within the tissue, namely.
Figure 3. Comparison of the numerical predictions to the experimental data from Schneiderman et al (1995) [58]. The steady-state free
IGF-I and its small complex concentrations in cartilage superficial zone (S) and middle & deep zone (M & D) are normalized to their synovial fluid
concentrations. It can be seen that the experimental results are described remarkably well by a set of parameters, i.e., free IGF half-life = 20 min, free
IGFBP half-life = 100 min and mass transfer coefficient kBP = kSC =5.5610
28 m/s.
doi:10.1371/journal.pone.0066870.g003
Figure 4. Diffusion of free IGF-I and –II, insulin, two functional groups of IGFBPs and their complexes from synovial fluid into
cartilage. The free IGF-I and its complex concentrations are normalized to their respective concentrations in synovial fluid.
doi:10.1371/journal.pone.0066870.g004
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Where c
f
1 = concentration of free IGF-I, c
f
2 = concentration of
free IGF-II, c
f
3 = concentration of free Insulin, c
f
BP1 = concen-
tration of the first functional group of free IGFBPs (i.e. IGFBPs 1–
5), c
f
BP2 = concentration of the second functional group of free
IGFBPs (i.e. IGFBP-6), c
f
SC11 = concentration of free IGF-I and
IGFBPs 1–5 complex, c
f
SC21 = concentration of free IGF-II and
IGFBPs 1–5 complex, c
f
SC22 = concentration of free IGF-II and
IGFBP-6 complex, cIR1 = concentration of IGF-IR and IGF-I
complex, cIR2 = concentration of IGF-IR and IGF-II complex,
cIR3 = concentration of IGF-IR and Insulin complex, cIIR2 =
concentration of IGF-1IR and IGF-II complex, cR1 = concen-
tration of IR and IGF-I complex, cR3 = concentration of IR and
Insulin complex, DIGF = diffusion coefficient of free IGFs in
tissue, DBP = diffusion coefficient of free IGFBP in tissue,
andDSC = diffusion coefficient of free complex in tissue.
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Figure 5. Steady-state concentrations of ligands (i.e. IGF-I, IGF–II and insulin) and their corresponding receptor (i.e. IGF-IR, IGF-IIR
and IR) complexes within the cartilage. The calculated complex concentrations are normalized to the total receptor concentration (i.e. cRT0 =
0.6 nM).
doi:10.1371/journal.pone.0066870.g005
Table 1. Parameters used for fitting equations (27)–(34) to the data of Schneiderman et al [58].
Parameter References and comments
Diffusion coefficient of IGF-I and –II (7.6 kDa) (DIGF) (2–4)610
27 cm2/s [75]
Diffusion coefficient of insulin (5.8 kDa) (DINS) 2610
27 cm2/s [76]
Diffusion coefficient of IGFBP (DBP) (0.6–1.3)610
27 cm2/s [22]
Diffusion coefficient of small complex (DSC) (0.6–1.3)610
27 cm2/s [22]
Free IGF-I concentration in human synovial fluid (cf10) 0.066 nM [19,58]
Free IGF-I small complex concentration in human synovial fluid (cfSC110) 2.6 nM [58]
Insulin concentration in human synovial fluid (cf30) 0.2–0.8 nM in serum [61]
Total receptor concentration (cRT) 0.6 nM [22]
Equilibrium dissociation constant for IGF-I and IGFBPs 1–5 (KD11 = k211/k+11) 4.8 nM [43]
Equilibrium dissociation constant for IGF-II and IGFBPs 1-5 (KD21 = k221/k+21) 5.2 nM [43]
Equilibrium dissociation constant for IGF-II and IGFBP6 (KD22 = k222/k+22) 5.7 nM [43]
Association rate constant for IGF-I and –II and IGFBPs (k+11, k+21 and k+22) (0.1–9)610
5 M21s21 [43]
Equilibrium dissociation constant for IGF-I and IGF-IR (KD11R = k211R/k+11R) 1.4 nM [71]
Equilibrium dissociation constant for IGF-II and IGF-IR (KD21R = k221R/k+21R) (2,15)6KD11R [32]
Equilibrium dissociation constant for insulin and IGF-IR (KD31R = k231R/k+31R) (50,100)6KD11R [32,77]
Equilibrium dissociation constant for IGF-II and IGF-IIR (KD22R = k222R/k+22R) 0.017,0.7 nM [32]
Equilibrium dissociation constant for insulin and IR (KD33R = k233R/k+33R) 0.1 nM [47]
Equilibrium dissociation constant for IGF-I and IR (KD13R = k213R/k+13R) (50,100)6KD33R [32,77]
Associate rate for IGF and receptors (k+11R, k+21R, k+31R, k+22R and k+11R) (1.8–4.5)610
5 M21s21 [22]
Receptor internalization rate (k10, k20, k30) (0.5–3)6 KD11R6k+11R[22]
doi:10.1371/journal.pone.0066870.t001
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Note subscript ‘SC’ refers to the so-called ‘small binary
complex’ formed between IGF and IGFBPs [58].
IGFs and their receptors
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Where cIR = concentration of type I receptors (i.e. IGF-IR), cIIR
= concentration of type II receptors (i.e. IGF-IIR), and cR =
concentration of Insulin receptors (i.e. IR).
By adding Equations (9)–(12), (13)–(14), and (15)–(17) respec-
tively, we obtain
L cIRzcIR1zcIR2zcIR3
 
Lt
~0 ð18Þ
L cIIRzcIIR2
 
Lt
~0 ð19Þ
L cRzcR1zcR3
 
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Thus, cIRzcIR1zcIR2zcIR3~n1, cIIRzcIIR2~n2 and
cRzcR1zcR3~n3, where ni are constants which can be obtained
from the initial condition, that is
cIRzcIR1zcIR2zcIR3~cIR0zcIR10zcIR20zcIR30 ð21Þ
cIIRzcIIR2~cIIR0zcIIR20 ð22Þ
cRzcR1zcR3~cR0zcR10zcR30 ð23Þ
where
cIR t~0ð Þ~cIR0, cIR1 t~0ð Þ~cIR10,
cIR2 t~0ð Þ~cIR20, cIR3 t~0ð Þ~cIR30
ð24Þ
cIIR t~0ð Þ~cIIR0, cIIR2 t~0ð Þ~cIIR20 ð25Þ
cR t~0ð Þ~cR0, cR1 t~0ð Þ~cR10,
cR3 t~0ð Þ~cR30
ð26Þ
Substituting equations (21)–(23) into equations (1)–(3) and (9)–(17)
respectively, and by letting
Lci
Lt
~0, we obtain the following set of
steady-state governing equations.
Figure 6. The effects of the ratios of IGF-I, IGF-II and insulin on normalized steady-state IGF-IR complex concentration. The calculated
complex concentrations are normalized to total receptor concentration (i.e. cRT0 = 0.6 nM). Free IGF half-life = 20 min, free IGFBP half-life = 100 min,
mass transfer coefficient kBP = kSC =5.5610
28 m/s, and cf10 =0.066 nM.
doi:10.1371/journal.pone.0066870.g006
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SC22~0 ð34ÞFigure 7. Steady-state IGF-I/IGF-IR, IGF–II/IGF-IR, insulin/IGF-IRand total IGF-IR complex concentration in cartilage under
various insulin to IGF-I ratios in synovial fluid. The calculated
complex concentrations are normalized to total receptor concentration
(i.e. cRT0 = 0.6 nM). Free IGF half-life = 20 min, free IGFBP half-life =
100 min, mass transfer coefficient kBP = kSC = 5.5610
28 m/s, and
c
f
10 =0.066 nM.
doi:10.1371/journal.pone.0066870.g007
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IGF and their receptors
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Boundary conditions
At the cartilage surface (i.e. x=0) it is assumed that IGF-I and –
II are in a reversible equilibrium with their binding partners (i.e.
IGFBPs) in synovial fluid. That is:
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wherec
f
10, c
f
20, c
f
BP10, c
f
BP20, c
f
SC110,c
f
SC210 and c
f
SC220 are concen-
trations of IGF-I and –II, two functional group IGFBPs and their
complexes in synovial fluid respectively.
At the cartilage surface (i.e. x=0) we assume that the
concentration of IGF is continuous between the synovial fluid
and the cartilage i.e. c
f
1(0,t)~c
f
10andc
f
2(0,t)~c
f
20. Due to the
relatively large molecular size of IGFBPs and the small complex in
relation to the pore openings at the surface of the cartilage, we
treat IGFBPs differently to IGF. Specifically, the solute flux from
fluid phase (i.e. synovial fluid) to the surface of the porous tissue (i.e.
cartilage) can be characterized by a fluid phase mass transfer
coefficient [59]. That is, here we assume the following mass flux
boundary conditions to describe the relatively large molecules (i.e.
IGFBPs and the small complexes) from the synovial fluid into the
cartilage tissue:
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where kBP and kSC are mass transfer coefficients for IGFBP and
small complex respectively. The mass transfer coefficient controls
the transport of free IGFBP and the small complex between the
synovial fluid and cartilage (porous) tissue.
At the bottom layer of the cartilage (i.e. x=1.5 mm) (which is
also the surface of subchondral bone), we assume the flux of all
components equals zero (i.e. insulation boundary condition).
In this study, we specifically focus on two questions. First, what
are the key factors (parameters) that govern the IGF-IR complex
concentration within cartilage tissue? Second, how might cells
regulate their IGF-IR complex concentration by the exposure to
the two IGFs and insulin? To achieve these two objectives, we first
calibrate the computational model by using experimental findings
for the IGF system within the body and in articular cartilage.
More specifically, the steady-state governing equations (27)–(40)
were solved numerically using the commercial finite element
software COMSOL stationary nonlinear solver [60] with the aim
of obtaining a set of model parameters that could reproduce the
observed experimental behavior in cartilage. Once calibrated, the
model is then employed to predict interactions between ligands
(e.g. IGF-I and –II, insulin) and their corresponding receptors (e.g.
IGF-IR, IGF-IIR and IR) under various physiological conditions
through parametric and sensitivity studies.
Figure 8. Steady-state IGF-I/IGF-IR, IGF-II/IGF-IR complex and total IGF-IR concentration under various ratios of two functional
IGFBP groupings in synovial fluid. The calculated complex concentrations are normalized to total receptor concentration (i.e. cRT0
=0.6 nM). Free IGF half-life = 20 min, free IGFBP half-life = 100 min, mass transfer coefficient kBP = kSC =5.5610
28 m/s, and cf10 = 0.066 nM.
doi:10.1371/journal.pone.0066870.g008
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Results and Discussions
Model calibration
Our computational model involves 23 parameters. Fortunately,
most of these parameters may be obtained from well-documented
experimental and theoretical studies, as detailed in Table I Tables.
Table. However, due to the paucity of direct quantitative
measurements in tissues, we must estimate some of the model
parameters, specifically the half-life of free IGF and IGFBP within
tissue, and the discontinuity in the concentration of macromole-
cules between the synovial fluid and the tissue’s external surface.
Moreover, we make the following assumptions.
N The total receptor concentration (cRT0) in cartilage (with
respect to the whole cartilage volume) is estimated to be
0.6 nM [22], but the greatest uncertainty relates to the
distribution of different types of receptors on the surface of a
tissue cell (i.e. chondrocyte). As a first estimate, we assume IGF-
IR, IGF-IIR and IR are equally distributed on the surface of a
tissue cell (i.e. cIR0 = cIIR0 = cR0), although this assumption will
be examined in a parametric study.
N As IGFBP and SC have similar molecular weights, we assume
thatkBP&kSC .
N The insulin concentration in synovial fluid is assumed to be
similar to that in human plasma (i.e. 0.2–0.8 nM in human
plasma [61]). The effect of varying this insulin concentration
will be tested in a parametric study.
Schneiderman et al [58] experimentally studied the concentra-
tion and molecular size distribution of IGF-I and its complexes in
human synovial fluid and cartilage. Human synovial fluid and
femoral heads were obtained from both male and female patients
(age range 20–90). The concentrations of free IGF-I and its small
binary complex (SC) in synovial fluid, cartilage surface layers
(approximately 0.2 mm thick) and the remainder (‘‘middle and
deep’’ zone of the cartilage) were estimated using ultrafiltration
membranes (20–100 kDa) followed by a radioimmunoassay of
each fraction. The results showed significantly higher concentra-
tions of free IGF-I and its small complex in the ‘superficial zone’
(S) of the tissue, relative to that in the ‘middle and deep’ zone (M &
D) of the tissue (see Figure 3). Most interestingly, it was also
observed that the free IGF-I concentration in the superficial zone
is over 40% higher than that in synovial fluid. It is noted that a
single species diffusion model does not predict this finding
(assuming negligible production of the species within the tissue,
one would expect concentrations in the tissue to be less than or
equal to the synovial fluid concentrations).
In relation to the current study, the experimental observations
reported by Schneiderman et al (1995) can be used to estimate the
unknown model parameters. That is, we will now proceed to
optimize unknown model parameters (specifically optimize the
half-lives of two IGFs and their IGFBPs (the same half-life for both
groups of IGFBPs), and the mass transfer coefficients of IGFBPs
and small complexes between the synovial fluid and cartilage
external surface) so as to achieve a best match to the above-
mentioned experimental observations.
In plasma, the half-life of free IGF is 10–15 minutes [62] while
IGFBP has a longer half-life of about 30–90 minutes [32]. In
addition, previous studies on transport of 14C-mannital across
specific peritoneal tissue surfaces in the rat showed that estimated
mass transfer coefficient in liver, stomach, intestines, colon and
uterus is around (1,40)61028 m/s [63]. This valuable informa-
tion provides a touchstone for our model calibration. Figure 3
presents the results of the experimental data fitting, which is
focused on the half-lives of free IGF and IGFBP and the mass
transfer coefficients of IGFBP and small complex (SC) (i.e. kBPand
kSC ). Also included in Figure 3 for comparison, are the
experimental results of Schneiderman et al. [58]. It is found that
these experimental results can be described by the model using
IGF-I t1/2 = 20 min, IGFBP t1/2 = 100 min for half-lives in
cartilage and a mass transfer coefficient kBP = kSC
=5.561028 m/s (which is within the range of values reported
above). Note, this single set of parameters can simultaneously
reproduced the experimental observations of depth dependent free
IGF-I and SC distributions.
As shown in Figure 3a, the overall steady-state free IGF-I
uptake is mainly governed by its half-life within the tissue – the
longer the half-life of free IGF, the higher the free IGF-I
concentration throughout the tissue. In contrast, the IGF half-
life appears to have limited influence on free SC uptake. Figure 3b
shows that the steady-state free IGF-I concentration in the tissue
superficial zone is strongly influenced by the half-life of IGFBP.
The faster the degradation of free IGFBP, the greater the release
of free IGF from the small complex. This increases the free IGF in
the tissue superficial zone. A shorter half-life of IGFBP reduces the
distance the free SC is transported into the deeper regions of the
cartilage.
A lower mass transfer coefficient means that less free IGFBP
and SC in the synovial fluid manages to penetrate the surface of
the cartilage tissue per unit time, and will result in a lower IGF and
SC concentrations in the tissue. It can be seen from Figure 3c that
the model results fit the experimental data reasonably well when
kBP = kSC =5.5610
28 m/s. The outcome of data fitting is
encouraging, though it is acknowledged that experimental data is
limited, and the model clearly needs to be further reassessed in the
light of additional experimental data sets.
By employing model parameters estimated from data fitting
(Figure 3), the estimated steady-state free IGF-I and SC
concentration profiles throughout the tissue are shown in Figure
4. The calculated concentration of free IGF-I and its complex are
normalized to their respective concentrations in synovial fluid. The
numerical results show that there is a significantly higher
concentration of free IGF-I in the superficial zone (0–0.2 mm) of
the cartilage, which is well above the ‘source concentration’ of free
IGF-I in synovial fluid. This computational result is consistent with
the experimental observations [58]. Maximum free IGF concen-
tration (c
f
1=c
f
10&1:5) occurs at around 0.2 mm from the tissue’s
external surface, but then decreases with increasing depth in the
tissue, reaching about 10% of the synovial fluid IGF concentration
in the deepest regions of the cartilage (i.e. 1.5 mm). The model
predicts that the free SC concentration immediately inside the
tissue surface is around 60% of that in synovial fluid. The results in
Figure 4 are sensible because of the selective degradation of the
IGFBPs by proteases, which results in an internal maximum
normalized free IGF-I ratio inside the cartilage itself. Our recent
study [33] theoretically demonstrated that reversible binding (i.e.
IGF-I and IGFBP3) plus preferential degradation of free IGFBP3
significantly increases of IGF-I uptake into the cartilage tissue. We
Figure 9. Steady-state IGF-I/IGF-IR, IGF-II/IGF-IR and total IGF-IR complex concentration under various ratios of the half-life of two
functional IGFBP groupings. The calculated complex concentrations are normalized to total receptor concentration (i.e. cRT0
=0.6 nM). Free IGF half-life = 20 min, cfBP10~c
f
BP20, mass transfer coefficient kBP = kSC = 5.5610
28 m/s, and cf10 =0.066 nM.
doi:10.1371/journal.pone.0066870.g009
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note that our results for the complete IGF system, shown in Figure
4, are consistent with our previous findings.
The calibrated model can now be employed to predict the
concentration of ligand/receptor complex distribution throughout
the tissue for a range of perturbations to this system. The focus is
on the ligand/receptor complex as a model output as the binding
of IGF-I, -II and insulin to IGF-IR receptors initiates intracellular
signaling and the subsequent cell response.
Figure 5 shows the steady-state concentrations of ligands (i.e.
IGF-I, IGF–II and insulin) and their corresponding receptor (i.e.
IGF-IR, IGF-IIR and IR) complexes within the cartilage. It can be
seen that the steady-steady ligand/receptor complex concentration
is much higher in the superficial zone compared to that in M & D
zone. The numerical outcomes are consistent with various studies
which postulated that articular cartilage superficial zone represents
an important signaling centre that is involved in regulation of
tissue development and growth [64,65]. For example, the
experimental studies of Hayes et al. indicated that the tissue near
the articular surface may contain a population of progenitor cells
that are responsible for the appositional growth during early
development of the tissue instead of interstitial growth [65]. Figure
5a is also shown that only a small portion of cell surface receptors
are bound to IGFs. The simulation outcomes indicated that most
of the cell surface receptors are inactive in normal conditions.
Indeed, based on the experimentally measured receptor concen-
tration in cartilage and binding affinity of IGF to IGF-IR which
are shown in Table 1, and our model, we can for the first time
confidently predict the what the occupancy for IGF-IR actually is
in the tissue.
Parametric studies
The ratios of IGF-I, IGF-II and insulin. A poorly
understood but apparently important mechanism worthy of
further investigation is the ratio between IGF-I and IGF-II within
tissue. Recent evidence has indicated that high IGF-II concentra-
tion in circulation may lead to an increased risk for developing
breast, prostate, colon and lung cancer [25]. There is reportedly a
4-fold increase of the total IGF-I/IGF-II ratio in OA synovial fluid
[26].
By fixing free IGF-II and IGFBP concentrations in synovial
fluid (i.e. c
f
20 =0.66 nM) and varying synovial fluid IGF-I
concentration, the model predicts that in OA condition, the 4-
fold increase of IGF-I significantly increases IGF-I/IGF-IR
complex concentration in the the superficial zone by around
30%, whilst has little impact on IGF-II/IGF-IR complex
concentration (see Figure 6a and Figure 6b). Presumably this
would enhance IGF-I mediated biological activity but have little
influence on IGF-II induced cellular activities. Further, it can be
seen that only very high concentration of insulin can influence
IGF-I/IGF-IR complex concentration (Figure 6c). Most impor-
tantly, it seems only 10% IGF-IR is complexed with ligand with
around 1% with IGF-I.
Turning our attention to the influence of insulin on the IGF-I/
IGF-IR, IGF-II/IGF-IR and insulin/IGF-IR formation, Figure 7
suggests that insulin only has an effect at very high insulin
concentrations (i.e.c30=c10w100, cf10 =0.066 nM) due to its
relatively low binding affinity of insulin for IGF-IR. The
computational model suggests that a higher insulin concentration
(i.e. c30=c10w1000) could potentially decrease IGF-I/IGF-IR and
IGF-II/IGF-IR complex concentration in the cartilage superficial
zone (Figure 7a-b) but significantly increase insulin/IGF-IR
complex formation (Figure 7c) and the total IGF-IR complex
formation throughout the tissue (Figure 7d). The normal range of
concentration of insulin is 0.2–0.8 nM in human plasma [61]. Any
significant difference in unlikely to be seen without at least an
order of magnitude increase in plasma concentration of insulin.
Although IGF-IR is highly specific to IGF-I and –II, insulin can
still activate IGF-IR at higher tissue concentrations (i.e. .10 nM
Figure 10. Normalized steady-state total IGF-IR complex concentration under various distribution of IGF-IR, IGF-IIR and IR
receptors. The calculated complex concentration is compared to total receptor concentration. Free IGF-I half-life = 20 min, free IGFBP half-life
= 100 min, mass transfer coefficient kBP = kSC = 5.5610
28 m/s.
doi:10.1371/journal.pone.0066870.g010
Figure 11. Normalized steady-state total IGF-IR complex concentration under various ligand/receptor half-lives. The calculated IGF-IR
complex concentration is compared to total receptor concentration. Free IGF-I half-life = 20 min, free IGFBP half-life = 100 min, mass transfer
coefficient kBP = kSC =5.5610
28 m/s.
doi:10.1371/journal.pone.0066870.g011
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or c30=c10w100) [66]. A recent study on the effect of insulin on
proteoglycan synthesis in porcine articular cartilage explants
showed that insulin at 10 nM increased proteoglycan synthesis
by 240% and inhibited the IL-1 induced proteoglycan catabolism
[67].
The ratios of two functional IGFBP groupings. Research
on IGFBP-6 is relatively limited compared to research on IGFBPs
1–5. As far as known, IGFBP6 preferentially binds IGF-II
compared with IGF-I [40,41,42]. The IGFBP6 content within a
tissue varies between species, e.g., IGFBP6 is one of the major
IGFBPs in bovine cartilage [44], and yet its concentration is too
small to be detected in normal human cartilage [26]. While the
knowledge of IGFBP6 is relatively limited, using the computa-
tional model we can explore the functional role of IGFBP6 in
modulating IGF bioavailability in tissue. Figure 8 shows the effect
on the steady-state total IGF-IR complex concentration in the
cartilage of varying the ratio of the two IGFBP functional groups
in the synovial fluid (i.e. c
f
BP20
.
c
f
BP10). As IGF-I and –II, and the
two functional groups of IGFBPs and their complex are in
reversible equilibrium in synovial fluid, a higher c
f
BP20
.
c
f
BP10 ratio
(e.g.c
f
BP20
.
c
f
BP10~10) indicates that much more IGF-II is trans-
ported into the cartilage, in comparison to IGF-I. Ultimately this
leads to a decrease in the steady-state IGF-I/IGF-IR complex
concentration throughout the tissue (Figure 8a) but a very
significant increase of the IGF-II/IGF-IR and total IGF-IR
complex concentration (Figure 8b–c).
The degradation of two functional IGFBP
groupings. IGFBP6 regulates the biological action of IGF-II
[68]. Studies have also shown that different proteases preferentially
target different IGFBPs for degradation. For example ADAM 12-S
degrades only IGFBP3, leaving IGFBP6 [34]. By fixing the half-
life of the first functional group of IGFBP (i.e. IGFBPs 1–5) and
varying the half-life of the second functional group of IGFBP (i.e.
IGFBP6), the model results shown in Figure 9 demonstrate that
IGFBP6 is capable of regulating the total IGF-IR complex
concentration via proteases mediated degradation of IGFBP6.
There is little data for humans, but during ‘reposition loading’ on
rabbit mandibular cartilage to adjust a occlusional defect, IGFBP6
expression underwent a 3-fold change in expression over the
35 day load period [69].
Most interestingly, although the half-life of IGFB6 has little
influence on IGF-I/IGF-IIR complex formation, the IGFBP6
degradation has a spatial dependent effect on the IGF-II/IGF-IR
and the total IGF-IR complex concentrations, i.e., a higher
degradation rate of IGFBP6 has obviously positive effect on IGF-
II/IGF-IR and total IGF-IR complex formation in the superficial
zone but some negative effects in the M & D zone.
The ratio of IGF-IR, IGF-IIR and IR on the surface of a
tissue cell. The kinetics of competition of ligands (e.g. IGF-I and
–II, insulin) for cell surface receptors (e.g. IGF-IR, IGF-IIR and IR)
has been intensively studied for several decades [33,56–58]. Using
cartilage tissue from human knee joints as an example, experi-
mental studies showed that there are approximately 18,000
chondrocytes /mm2 per 350 mm (thick) on average [70], and
about 20,000 receptors per cell [71].However, there is little
experimental information about the actual distribution between
IGF-IR, IGF-IIR and IR on the surface of a cell. Furthermore,
this distribution is likely to differ from species to species as well as
from tissue to tissue.
Thus, a series of parametric studies are carried out here to
investigate the effect of this receptor distribution and receptor
density on IGF-IR complex formation. By varying different types
of receptor distribution, while fixing the total number of cells
within a tissue, it can be seen (in Figure 10) that receptor
distribution has little influence on total IGF-IR complex concen-
tration when the number of receptors per cell is relatively low (e.g.
20,000 receptors per chondrocyte in human cartilage). However,
this distribution has some effect for a tissue with much higher
receptors per cell (i.e. .200,000 receptors per cell). It is thought
that the inhibitory effects of IGFBPs on IGF-I and –II are largely
due to the higher affinity of the two IGFs for IGFBPs than that of
IGF-IR [1,35]. Our simulation results show that this ‘‘blocking’’
capability of IGFBPs gradually deteriorates with the increase in
the receptor concentration (relative to the IGFBP concentration).
By fixing the fraction of IGF-IR (i.e. 33% of total receptor types
per cell), it can be seen from Figure 10b–c that the total IGF-IR
complex concentration changes inversely with the IGF-IIR
fraction. The results presented here demonstrate that IGF-IIR
Figure 12. Steady-state total IGF-IR complex concentration under various IGF-IIR concentrations. The calculated IGF-IR complex
concentration is compared to total receptor concentration. Free IGF-I half-life = 20 min, and mass transfer coefficient kBP = kSC =5.5610
28 m/s.
doi:10.1371/journal.pone.0066870.g012
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could influence the complex formation between IGF-II and IGF-
IR e.g. by functioning as an IGF-II clearance receptor.
Finally, Figure 10c indicates that at very high receptor
concentration, most of the IGFs and insulin are consumed within
the tissue superficial zone, and thereby have little chance of
reaching into the deep region of the tissue.
Ligand / receptor half-life. IGF signaling depends on the
conversion of the interaction between ligand (IGF-I, IGF-II and
insulin) and IGF-IR into changes in cell biology. As shown in
Figure 11, in this study, we theoretically studied the effects of
ligand / IGF-IR complex half-lives (i.e. the receptor internaliza-
tion rate following the binding of ligand to IGF-IR) on total
steady-state IGF-IR complex concentration. By fixing the half-life
of free IGF (i.e. t1/2 = 20 min), it is demonstrated that
chondrocytes can regulate their own exposure to free IGF by
controlling the ligand internalization rate, k0. These simulation
results are consistent to other relevant research studies [72,73].
IGF-IIR concentration. Figure 12 shows a strong connection
between IGF-IIR concentration and IGF-IR signaling through
modifying total IGF-IR complex concentration. The results
demonstrate that IGF-IIR could function as a ‘‘clearance
receptor’’ by removing IGF-II from the matrix environment.
These observations are consistent to the research studies on the
roles of the IGF system in cancer growth and metastasis which
indicate that IGF-IIR are negative effectors that mediate the IGF-
IR signaling and function [14].
Sensitivity analysis. A sensitivity analysis can be used to
identify the dominant parameters in the IGF system affecting a
state variable of interest. In our case the state variable of interest is
the total IGF-IR complex concentration as it is this concentration
regulating the subsequent intra-cellular signaling. Identifying the
parameters to which the system is most sensitive helps focus future
experiments, as reducing the uncertainty in these parameters has
most impact on reducing model uncertainty. Further, the tissue (or
clinician through the administration of drugs) may target the
parameters identified by a sensitivity analysis to efficiently control
the system. Indeed, if there are several parameters that strongly
influence the system, then all these parameters may need to be
controlled simultaneously to control the system. We return to this
point later in the discussion.
The basis of a sensitivity analysis is systematically varying one
parameter at a time and observing the corresponding change in
the system output of interest. This implies performing the
sensitivity analysis about a ‘base’ set of model parameters that
represents the operating point of the system. For the operating
point, here we use the model parameters optimised to reproduce
the cartilage experimental data of Schneiderman et al (1995) [58]
(i.e. free IGF-I half-life = 20 min, free IGFBP half-life = 100 min,
mass transfer coefficients kBP = kSC =5.5610
28 m/s). As for the
insulin, its concentration in normal human plasma (i.e. 0.5 nM)
[61] is treated as the base value for this sensitivity analysis.
However, it is important to note that due to system non-linearities,
the set of parameters to which a system is most sensitive may
change if a new system operating point (and set of base
parameters) were to be chosen.
We start with the calculation of the ‘base’ amount of total IGF-
IR complex within the cartilage using COMSOL sub-domain
integration (i.e. IIGF-IR complex_base). Then, the value of each
parameter is systematically varied ranging over six orders of
magnitude (from 0.001,1000) of its base value to explore the
change of total IGF-IR complex concentration (i.e. IIGF-IR complex)
with respect to IIGF-IR complex_base in the superficial zone, M & D
zone and the overall tissue respectively.
Figure 13. Sensitivity analysis of model parameters on steady-state total IGF-IR complex concentration integrated over cartilage
superficial zone, middle & deep zone and overall tissue respectively. The calculated sub-domain integration (i.e. IIGF-IR complex) is compared
to its base value (i.e. IIGF-IR complex-base). The base values of model parameters (i.e. half-life of free IGF, IGFBP and ligand/receptor, mass transfer
coefficient and insulin) are obtained from model calibration using the experimental data from Schneiderman et al (1995) [58] (i.e. free IGF-I half-life
= 20 min, free IGFBP half-life = 100 min, IGF-IIR concentration = 20 nM, mass transfer coefficient kBP = kSC = 5.5610
28 m/s) while the base value of
insulin concentration = 0.5 nM reported in normal human serum [61].
doi:10.1371/journal.pone.0066870.g013
Figure 14. Normalized steady-state total IGF-IR complex concentration when free IGFBP half-life is equal to 10% of its base value
(i.e. 10 min). The calculated IGF-IR complex concentration is compared to total receptor concentration. Free IGF-I half-life = 20 min, and mass
transfer coefficient kBP = kSC = 5.5610
28 m/s.
doi:10.1371/journal.pone.0066870.g014
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In this study, we mainly focus on some of the model parameters
which are not well understood in the cartilage so far (i.e. half-lives
of free IGF and IGFBP within the tissue, mass transfer coefficient
of IGFBP, IGF-IR concentration, IGF-IIR concentration and its
consumption rate, and concentration of insulin). The results
appear in Figure 13. IGF-IR concentration apparently is the most
sensitive parameter. It indicates that the most effective way of
controlling the IGF system is through activating and deactiving of
IGF-IR. The half-life of IGF is also shown to be one of the most
critical parameters governing the concentration of IGF-IR
complex within the tissue and its effect appears to be strongly
depth dependent. For example, a 10-fold increase of the base value
of free IGF half-life could potentially increase total IGF-IR
complex formation by around 36% in the superficial zone, 450%
in M & D zone and 300% throughout the tissue. Further, our
results suggest that an optimal IGFBP degradation rate may be
different in the superficial zone and M & D zone if the goal is to
maximize IGF-IR complex formation. That is a trade-off exists
between maximizing superficial versus M & D zone receptor
complex formation. Interestingly, the calibrated model (and
presumably the cartilage) is operating with an IGFBP degradation
rate that gives the optimal overall (tissue averaged) receptor
complex concentration. That is, the magnitude and direction of
IGFBP degradation gradient offers the control over the system. As
shown in Figure 13a, one tenth of the base value of IGFBP half-life
appears to be the optimal half-life of IGFBP in superficial zone
(increase IGF-IR complex by 52% in superficial zone) whilst the
base value of IGFBP half-life appears to be the optimal value in M
& D zone. The depth dependent total IGF-IR complex
concentration profile under the optimal half-life of free IGFBP
in superficial zone (i.e. 10 min which is 10% of its base value) is
shown in Figure 14. It can been seen that this optimal half-life of
free IGFBP leads to an significant increase of total IGF-IR
complex concentration in superficial zone but a relatively lower
complex concentration in M & D zone. The implication of these
results is that cartilage could optimize the exposure of IGF-IR to
IGF in different regions of the tissue by spatially adjusting the rate
of IGFBP degradation (i.e. the chondrocytes could ‘tune’ their
exposure to IGF by adjusting the rate of IGFBP protein
degradation). Further, a balance between IGF signaling and
controlling this signaling is of importance for chondrocytes to
maintain tissue homeostasis. Figure 13 shows that there is a
generally positive correlation between the mass transfer coefficient
and the total IGF-IR complex concentration. A mass transfer
coefficient less than the base value (i.e. 5.561028 m/s) could
potentially decrease total IGF-IR complex concentration but has
little influence once the value is greater than its base value. That is,
the mass transfer coefficient is not one of the major parts of the
control system used by chondrocytes to tune their exposure to
IGF.
Further, it demonstrates that, in comparison to other param-
eters, IGF-IIR concentration and its rate of consumption are two
critical parameters which could significantly influence the total
IGF-IR complex concentration. Previous studies have suggested
that IGF-IIR functions as a tumor suppressor, while the mutation
or loss of IGF-IIR in some human tumors is frequently observed
[74]. However, the actual suppressive mechanism of IGF-IIR has
not been well understood. Here we demonstrate the ability of IGF-
IIR to mediatie the IGF-IR signaling by regulating IGF-IIR
concentration or its turnover.
Indeed, our observations gain additional significance following
recent findings that new drugs designed to block the IGF-1R
receptor have been ineffective in blocking IGF signaling [17].
Allison’s suggestion that to block IGF signaling requires a ‘cocktail’
of drugs is consistent with our findings that there are several
systems that may independently control the level of IGF-IR
complexation. Potential homeostatic feedback systems exerting
strong control over IGF-1R signaling are the IGF-IIR concentra-
tion and its turnover, and the protease composition in the
extracellular environment surrounding the cell, which controls the
rate of degradation of IGF and its binding proteins.
Finally, the sensitivity analysis suggests that the formation of
IGF-IR complex is generally insensitive to insulin due to its
relatively low binding affinity to IGF-IR in comparison to IGFs.
However, a significant effect can be seen once the concentration of
insulin is over 10 times of the base value in superficial zone where
most of the IGFs and IGF-IR complexes in tissue are formed.
Conclusion
In this study, we have developed a comprehensive mathematical
model of the IGF system that may be applied to all tissues (Figure
2). The model is applied here to articular cartilage as appropriate
data is available for this tissue to calibrate the model. For this
tissue, our main findings are as follows:
N Calibrating the model to reproduce the available experimental
data by optimizing over a small subset of model parameters,
we have obtained an estimate for the half-lives of IGFs and
IGFBPs, mass transfer coefficients of IGFBPs and small
complexes within the tissue. Specifically we estimate in
cartilage IGF-I t1/2 = 20 min, IGFBP t1/2 = 100 min and a
mass transfer coefficient kBP = kSC =5.5610
28 m/s.
N The model predicts that the distribution of the steady-state
concentrations of free IGF-I and -II and their binary
complexes are strongly depth-dependent in cartilage, with
significantly higher free IGF-I concentration occurring in the
tissue superficial zone (0,0.2 mm), which is well above the
free IGF-I concentration in synovial fluid (by around 50%). It
is noted that this finding is cannot be reproduced by a simple
diffusion model, which predicts all concentrations within the
tissue are less than or equal to the concentration in the synovial
fluid.
N The half-life of free IGFs govern the steady-state free IGF
uptake throughout the tissue, whilst steady-state free IGF
concentration in the tissue superficial zone is largely dominat-
ed by the half-life of the free IGFBP.
N The majority of IGF molecules from the synovial fluid bind to
IGF receptors located in the superficial zone, which leads to
the spatial dependent free IGF distribution in cartilage.
N The occupancy of IGF-1R receptors throughout cartilage is
low, with more than 95% of these receptors unbound.
N The formation of IGF-IR complex is generally insensitive to
insulin in normal conditions. However, insulin concentrations
more than 10 times that normal human plasma could
significantly enhance overall IGF-IR complex concentration
in cartilage.
N Our sensitivity analysis shows that at the normal operating
point for cartilage, the receptor occupancy of the IGF-1R
receptor is most strongly influenced by the following variables:
the half-life of IGFBP, the half-life of free IGF, the IGF-IIR
concentration, the IGF-IIR receptor turnover and the mass
transport of IGF into the cartilage from the synovial fluid.
N It is likely that the chondrocytes can adjust their expression of
proteases to control the half-life of free IGF and its binding
proteins in their extracellular environment, and adjust their
concentration of IGF-1R and IGF-IIR receptors in the cell
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membrane, and adjust the rates of receptor turnover. By these
means, it is possible for chondrocytes to have some control
over their own IGF signalling level within the tissue.
Recent drugs developed to block IGF signaling through its
receptor have been disappointing in their therapeutic efficacy.
Consequently Allison [17] suggests that a cocktail of drugs is
required to block IGF signaling. Our analysis of IGF system is
consistent with this view. Potential homeostatic feedback systems
exerting strong control over IGF-1R signaling are the IGF-IIR
concentration and its turnover, and the protease composition in
the extracellular environment surrounding the cell, which controls
the rate of degradation of IGF and its binding proteins. We
conclude that a systems model of IGF in tissues can assist in
developing an understanding of the IGF system that is not possible
using experimental methods alone, and that this approach may be
useful in assessing the likely efficacy of proposed IGF drug
treatments that involve multiple targets.
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